Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesion. In chronic lymphocytic leukemia (CLL), Syk becomes activated by external signals from the tissue microenvironment, and was targeted in a first clinical trial with R788 (fostamatinib), a relatively nonspecific Syk inhibitor. Here, we characterize the activity of two novel, highly selective Syk inhibitors, PRT318 and P505-15, in assays that model CLL interactions with the microenvironment. PRT318 and P505-15 effectively antagonize CLL cell survival after BCR triggering and in nurse-like cell-co-cultures. Moreover, they inhibit BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT318 and P505-15 furthermore inhibit Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering. These findings demonstrate that the selective Syk inhibitors PRT318 and P505-15 are highly effective for inhibition of CLL survival and tissue homing circuits, and support the therapeutic development of these agents in patients with CLL, other B-cell malignancies and autoimmune disorders.
INTRODUCTION
Chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in Western countries, is characterized by expansion of monoclonal, mature B cells expressing CD5 and CD23. 1 Despite major therapeutic advances during the past years, such as introduction of chemo-immunotherapy, 2, 3 CLL remains incurable, and the next wave of therapeutic progress will likely be based on our better understanding and targeting of mechanism underlying CLL cell survival and expansion. Proliferation of CLL cells occurs in the tissue compartments (lymphatic tissues, bone marrow), where CLL cells form aggregates of activated, proliferating cell clusters called 'proliferation centers' or 'pseudofollicles', 4 accounting for a daily turnover of up to 1% of the entire clone. 5 Here, CLL cells are in intimate contact with various accessory cells that are not part of the CLL clone, such as T cells, 6, 7 actin (aSMA þ )-positive mesenchymal stromal cells, 8 and monocyte-derived nurse-like cells (NLCs). 9, 10 Cellular and molecular interactions with these cells, collectively referred to as the leukemia 'microenvironment', foster CLL cell survival, proliferation and drug resistance, and hence have become attractive new targets for therapy. Among the diverse molecular pathways of crosstalk between CLL cells and their microenvironment, B-cell receptor (BCR) signaling has been recognized as one of the central pathways, based on in vitro 11, 12 and in vivo data. 13 Supporting the importance of the BCR in CLL pathogenesis are the notions that prognosis of CLL patients correlates with the amount of somatic mutations in the variable regions of the BCR and that CLL cells express a restricted set of BCR with immunoglobulin (Ig) heavy chain variable (V) gene sequences that are identical or stereotyped in subsets of patients, suggesting that these BCRs bind similar antigens. Moreover, Ig-unmutated and/or ZAP-70-positive patients preferentially respond to BCR stimulation 14 and display gene expression profiles suggesting activation downstream of the BCR. 15 Finally, CLL cells isolated from lymph nodes display gene expression profiles indicating BCR activation. 13 BCR signaling is a complex process. The BCR is composed of an antigen-specific membrane Ig paired with Ig-a/Ig-b hetero-dimers (CD79a/CD79b).
Engagement of BCRs induces phosphorylation of immunoreceptor tyrosine-based activation motifs in the cytoplasmatic tails of Ig-a and -b, with subsequent recruitment of SYK to BCR microclusters, followed by phosphorylation of Syk tyrosine residues. Once activated, Syk phosphorylates several signal intermediates like Bruton's tyrosine kinase (Btk) and BLNK, which in turn activate the downstream signaling molecules nuclear factor-kB, Raf, mitogen-activated protein kinase MEK and extracellular signal-regulated kinase (ERK). Syk signaling is required for B-cell development, proliferation and survival of B cells. Sykdeficient mice show a severe defect of B lymphopoiesis, with a block at the pro-B to pre-B transition. Previous in vitro studies 16, 17 and a clinical trial 18 showed that disrupting BCR signals and microenvironmental interactions with the Syk inhibitor R406 (fostamatinib, also called FosD, or R788 in its oral formulation) is effective in CLL and other B-cell malignancies. R406 is an ATPcompetitive kinase inhibitor and has limited specificity toward SYK, and also displays activity against other kinases, such as FMSrelated tyrosine kinases 3 (FLT3), Lck, and Janus kinase 1 and Janus kinase 3. 19 Even through other kinase inhibitors of the same pathways, BTK and phosphatidylinositol 3 kinase, are being tested in CLL, there are no reported advanced clinical trials, which test the hypothesis of specific SYK inhibition in B-cell malignancies.
Therefore, we evaluated the activity of PRT318 and P505-15 for inhibiting CLL cell activation, survival and migration.
MATERIALS AND METHODS
CLL cell purification, cell lines, cell viability testing, reagents After informed consent, peripheral blood samples were obtained from patients fulfilling diagnostic and immunophenotypic criteria for CLL at the Leukemia Department at MD Anderson Cancer Center. Patient consent for samples used in this study was obtained in accordance with the Declaration of Helsinki on protocols that were reviewed and approved by the Institutional Review Board at MD Anderson Cancer Center. Peripheral blood mononuclear cells were isolated via density gradient centrifugation over Ficoll-Paque (GE Healthcare, Waukesha, WI, USA) and were used fresh or were placed into fetal bovine serum (FBS) (BD Biosciences, San Diego, CA, USA) plus 10% dimethylsulfoxide (SigmaAldrich, St Louis, MO, USA) for viable frozen storage in liquid nitrogen. The murine marrow stromal cell lines KUSA-H1 and 9 --15C were purchased from the Riken cell bank (Tsukuba, Japan) and maintained in RPMI 1640 medium supplemented with 2.05-mM L-glutamine (HyClone, Logan, UT, USA), 10% FBS (SAFC Biosciences, Lenexa, KS, USA), and penicillin --streptomycin (Cellgro, Manassas, VA, USA). The murine stromal cell line TSt-4 derived from fetal thymus tissue (also from Riken) was maintained in RPMI 1640 medium supplemented with 2.05-mM L-glutamine, 5% FBS and penicillin --streptomycin. CLL cell viability was determined by analysis of mitochondrial transmembrane potential using 3,3 0 dihexyloxacarbocyanine iodide (Molecular Probes, Invitrogen, Eugene, OR, USA) and by cell membrane permeability to propidium iodide (Sigma-Aldrich). 16 The Syk inhibitors PRT318 (also called PRT-060318) and P505-15 (also called PRT062607) recently were described 20 --22 and were synthesized at Portola Pharmaceuticals (South San Francisco, CA, USA), dissolved in dimethylsulfoxide at 10 mM, and stored at À20 1C until use. PRT318 and P505-15 are novel small-molecule SYK inhibitors that are more selective and potent (SYK IC 50 ¼ 6 nM for P505-15, and 3 nM for PRT318) 21 than previously described SYK inhibitory compounds, such as R406 (SYK IC 50 ¼ 41 nM). Furthermore, the high degree of selectivity of PRT318 in an ambit kinase panel of 318 purified kinases.
23 P505-15 was similarly screened in the KinaseProfiler panel of 270 independent purified kinase assays, again demonstrating profound specificity for Syk. 22 CLL cell apoptosis in NLC co-cultures NLC co-cultures were established by suspending peripheral blood mononuclear cell from patients with CLL in complete RPMI medium with 10% FBS and penicillin --streptomycin --glutamine (HyClone) to a concentration of 10 7 cells/ml (total 2 ml). Cells were incubated for 14 days in 24-well plates (Corning Life Sciences, Corning, NY, USA) as previously described. 24 To evaluate whether the Syk inhibitors PRT318 and P505-15 could overcome the protective effect of NLC, CLL cells were cultured under standardized conditions on NLC or in suspension, in the presence or absence of PRT318 and P505-15. At the indicated time points, CLL cells were collected and assayed for cell viability as previously described. 16 
Enzyme-linked immunosorbent assays
To evaluate the effect of the Syk inhibitors PRT318 and P505-15 on CCL3 and CCL4 secretion after stimulation of CLL cells with anti-IgM (10 mg/ml) or with NLC, chemokine levels were measured in supernatants of activated CLL cells, as previously described. 16, 25 After 24 h of anti-IgM or NLC co-culture, supernatants were harvested and assayed for CCL3, CCL4 and CXCL13 (only in NLC co-cultures) by quantitative enzyme-linked immunosorbent assays according to the manufacturer's instructions (Quantikine, R&D Systems, Minneapolis, MN, USA). 
Chemotaxis assay
To evaluate the impact of PRT318 and P505-15 on CLL cell chemotaxis, we performed chemotaxis assays across polycarbonate Transwell inserts as described. 26 Briefly, CLL cells (10 7 /ml) were incubated at 37 1C in 5% CO 2 with 10 mg/ml of anti-IgM (MP Biomedicals, Solon, OH, USA) in complete RPMI medium with or without 2 mM PRT318 and P505-15. After 1 h, CLL cells were centrifuged and re-suspended in RPMI 1640 with 0.5% bovine serum albumin to a concentration of 10 7 cells/ml. In all, 100 ml of cell suspension was added to the top chamber of a Transwell culture insert (Corning Life Sciences) with a diameter of 6.5 mm and a pore size of 2 mm. Filters then were transferred to wells containing medium with or without 200 ng/ml of CXCL12 (Upstate Biotechnology, Charlottesville, VA, USA) or 1 mg/ml of CXCL13 (R&D Systems). The chambers were incubated for 3 h at 37 1C in 5% CO 2 . After this incubation, the cells in the lower chamber were suspended and divided into aliquots for counting with a FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA) for 20 s at 60 ml/min in duplicates. A 1/20 dilution of input cells was counted under the same conditions.
CLL cell migration beneath stromal cells (pseudoemperipolesis)
To determine the effects of the Syk inhibitors PRT318 and P505-15 on spontaneous migration of CLL cells beneath stromal cells, we quantified pseudoemperipolesis, as described. 26 Briefly, the murine stromal cells (9 --15C and TSt-4) were seeded the day before the assay onto collagencoated 12-well plates at a concentration of 1.8 Â 10
5 cells per well in RPMI 1640 supplemented with 10% fetal calf serum and penicillin --streptomycin --glutamine. CLL cells at a concentration of 10 7 /ml were incubated at 37 1C in 5% CO 2 in complete medium supplemented with or without 2 mM PRT318 or P505-15 for 30 min, before addition of 10 mg/ml of anti-IgM. After another 1-h incubation, CLL cells were then added to the stromal cell layers, and the plates were incubated at 37 1C in 5% CO 2 for 4 h. Cells that had not migrated into the stromal cell layer were removed by vigorously washing with RPMI medium for three times. The complete removal of nonmigrated cells and the integrity of the stromal cell layer containing transmigrated cells were assessed by phase-contrast microscopy and documented photographically. The stromal cell layers containing transmigrated cells were detached by incubation for 1 min with trypsin/EDTA prewarmed to 37 1C (Invitrogen, Carlsbad, CA, USA). Cells were then immediately suspended by adding 1 ml of ice-cold RPMI/10% FBS, washed and suspended in 0.4 ml of cold medium for counting by flow cytometry for 20 s at 60 ml/min in duplicates. Based on relative differences in size and granularity (forward scatter and side scatter) between cell types, a lymphocyte gate was set to exclude stromal cells from the counts. The number of migrated cells under each condition was expressed as percentage of the control.
Western blot
Freshly isolated CLL cells were cultured in suspension and stimulated with 10 mg/ml anti-IgM for 10 min in the presence or absence of PRT318 or P505-15. Cells then were lysed on ice for 30 min in lysis buffer containing 25 mM HEPES, 300 mM NaCl, 1.5 mM MgCl 2 , 0.5% sodium deoxycholate, 20 mM glycerophosohate, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 0.2 mM EDTA, 0.5 mM dithiothreitol, 1 mM sodium orthovanadate and protease inhibitor. Cells were centrifuged at 14 000 g for 15 min at 4 1C, and supernatant was stored at À80 1C until use. Protein content was determined using the detergent compatible protein assay kit, according to manufacturer's instructions (Bio-Rad Laboratories, Hercules, CA, USA). Aliquots (50 mg) of total cell protein were boiled with Laemmli sample buffer and loaded onto 4 --12% sodium dodecyl sulfate-polyacrylamide gradient gels and transferred to nitrocellulose membranes (GE Osmonics Labstore, Minnetonka, MN, USA). Membranes were blocked for 1 h in phosphate-buffered saline (PBS)-Tween containing 5% nonfat dried milk and incubated with primary antibodies either overnight or for 3 h followed by species-specific horseradish peroxidase-conjugated secondary antibody (diluted 1:10 000) for 1 h. The blots were visualized by enhanced chemiluminescence according to manufacturer's instructions (Pierce Biotechnology, Rockford, IL, USA) and normalized to the actin levels in each extract. Membranes were probed at 4 1C with the following primary antibodies: ERK1/2, phospho-ERK (Cell Signaling, Danvers, MA, USA), and b-actin (Sigma-Aldrich). Immunoreactive bands were visualized using peroxidase-conjugated secondary antibodies (GE Healthcare) and enhanced chemiluminescence detection system (Pierce Biotechnology, Rockford, IL, USA).
For were washed once in PBS, and then resuspended in 50% methanol in PBS (À80 1C) and stored overnight. Cells were then washed and resuspended in PBS containing 1% bovine serum albumin. For flow cytometry, antibodies were added to 0.5 Â 10 6 cells and incubated for 1 h at room temperature. Samples were washed PBS þ 1% bovine serum albumin and resuspended in 350 ml PBS þ 1% bovine serum albumin for assessment on a FACSCalibur (BD Biosciences).
Data analysis and statistics
Results are shown as mean±s.e.m. of at least three experiments each. As appropriate for the analysis, Student's paired or unpaired t-tests were used for statistical comparisons. Analyses were performed using GraphPad Prism 4 software for Macintosh (GraphPad Software, San Diego, CA, USA). A P-value o0.05 was considered as statistically significant. Flow cytometry data were analyzed using the FlowJo software (TreeStar, Ashland, OR, USA).
RESULTS

SYK inhibition induces CLL apoptosis and abrogates BCR-derived survival signals
BCR cross-linking with anti-IgM induces BCR activation, which can protect CLL cells from undergoing spontaneous apoptosis. 16, 27 As shown in a representative case in Figure 1a , the SYK inhibitors PRT318 and P505-15 abrogated the pro-survival effect of anti-IgM and induced CLL cell apoptosis. Figure 1b SYK inhibitors antagonizes NLC-mediated CLL cell survival NLC co-cultures activate CLL cells via multiple mechanisms, protect CLL cells from apoptosis and represent an in vitro system to model the lymphatic tissue microenvironment in CLL. PRT318 and P505-15 were therefore tested in this relevant model system. Figure 2a displays CLL cell viabilities in a representative case, co-cultured with NLC in the presence and absence of PRT318 or P505-15. CLL cell viability in co-cultures with NLC was significantly reduced by the Syk inhibitors; viability in the presence of 2 mM/ml PRT318 was reduced to 73% (±8%) and to 51% (±8.3%) by 2 mM/ml P505-15 after 48 h (mean ± s.e.m., Po0.05, n ¼ 7, Figure 2b ).
PRT318 and P505-15 inhibit anti-IgM-and NLC-induced secretion of the chemokines CCL3, CCL4 and CXCL13 Anti-IgM-and NLC-activated CLL cells secrete the chemokines CCL3 and CCL4, which appears to correlate with the signaling capacity of the BCR. 25, 28 We measured the concentration of CCL3 and CCL4 in supernatant from CLL cells cultured in medium, or medium supplemented with anti-IgM in the presence or absence of PRT318 or P505-15 after 24 h. As displayed in Figure 3a , PRT318 and P505-15 inhibited the increased secretion of CCL3 and CCL4 after anti-IgM stimulation. The mean ( ± s.e.m.) CCL3 and CCL4 concentrations in supernatants of CLL cells after anti-IgM stimulation were 8400±1166 pg/ml of CCL3 and 8959±2147 pg/ml of CCL4. Treatment of CLL cells with PRT318 significantly decreased anti-IgM-induced CCL3 and CCL4 levels to 4425 ± 668 pg/ml (CCL3, n ¼ 7, Po0.05) and 4144 ± 1053 pg/ml (CCL4, n ¼ 7, Po0.05). P505-15 also significantly decreased chemokine levels to 2263±744 pg/ml (CCL3, n ¼ 7) and 2250 ± 1093 pg/ml (CCL4, n ¼ 7). Treatment with lower concentrations of PRT318 and P505-15 also reduced the secretion of CCL3 and CCL4 as shown in Figures 3c--d . As reported earlier, the secretion of CCL3 and CCL4 is also markedly increased in NLC co-cultures 24 and in activated CLL cells isolated from lymph nodes. 13 Figure 3b depicts significant levels of inhibition of NCL-induced secretion of CCL3 and CCL4 in CLL-NLC co-cultures in the presence of PRT318 and P505-15. The chemokine CXCL13 is also released in CLL-NLC co-cultures to foster cognate interactions between these two cell types. As shown in Figure 3e , CXCL13 was decreased from 599±204 pg/ml in control wells to 384±164 pg/ml in the presence of PRT318, and to 337 ± 144 pg/ml in the presence of P505-15 (mean ± s.e.m., P ¼ 0.05, n ¼ 5).
PRT318 and P505-15 inhibit chemotaxis of CLL cells CLL cells migrate toward the chemokines CXCL12 and CXCL13 after activation of the respective chemokine receptors (CXCR4, CXCR5). SYK is known to be involved in migration of normal and malignant B cells, such as CLL cells, 16, 17 via phosphorylation of the F-actin interacting protein SWAP-70. 29 As shown in Figure 4 , CLL cell chemotaxis toward CXCL12 was significantly decreased from 3632 ± 414 to 2331 ± 402 by RPT318, and to 2174 ± 450 by P505-15 (mean±s.e.m. number of migrated cells, P ¼ 0.05, n ¼ 6), while the mean (±s.e.m.) number of cells migrating toward CXCL13 decreased from 2361 ± 429 to 1742 ± 266 by PRT318 and to 1131 ± 266 by P505-15 (P ¼ 0.05, n ¼ 6).
PRT318 and P505-15 antagonize CLL cell migration beneath marrow stroma cells (pseudoemperipolesis) CLL cell migration beneath stroma cells represents a relevant assay for modeling CLL tissue homing. Given the mobilizing effect of SYK inhibition in CLL in a first clinical trial with fostamatinib, 18 we analyzed the effects of PRT318 and P505-15 on CLL cell pseudoemperipolesis. The phase-contrast photomicrographs in Figure 5a depict a significant reduction in CLL cell migration beneath 9 --15C and TSt-4 stromal cells after pre-treatment with PRT318 and P505-15 (2 mM/ml), when compared with controls. As shown in Figure 5b decreased from 18 553 ± 4683 to 3383 ± 709 after pre-treatment with 2 mM PRT-318 (mean ± s.e.m. number of migrated cells, P ¼ 0.05, n ¼ 14) and to 3171±1615 after pre-treatment with 2 mM P505-15 (P ¼ 0.05, n ¼ 14) using 9 --15C stromal cells, and from 10 900 ± 4260 to 2280 ± 604 (P ¼ 0.05, n ¼ 14) and to 2962±1192 (P ¼ 0.05, n ¼ 14) using TSt-4 stromal cells.
PRT318 and P505-15 block BCR-, CXCR4-, and CXCR5-signaling in CLL cells As depicted in Figure 6a , PRT318 and P505-15 both inhibited ERK phosphorylation in response to anti-IgM stimulation. Furthermore, P505-15 inhibited Syk phosphorylation in a dose-dependent manner, as shown in Figure 6b in SUDHL6 B cells. We also quantified P-ERK by flow cytometry. As shown in Figure 6c , treatment with P505-15 effectively blocks ERK phosphorylation after anti-IgM stimulation.
DISCUSSION
Robust preclinical 16, 30, 31 and first clinical evidence 18, 32, 33 supports that targeting BCR signaling is one of the most promising novel therapeutic approaches for treatment of patients with CLL, other B-cell malignancies and autoimmune diseases. Small molecule inhibitors of BCR-associated kinases Syk, 18 Btk 32 and phosphatidylinositol 3 kinase delta 34, 35 recently entered the clinical stage and show promising clinical activity in patients with B-cell lymphomas and leukemias, especially in patients with CLL. Constitutive and inducible activation of Syk in CLL 16, 36 and B-cell lymphomas 30, 37 makes this kinase particularly well suited for therapeutic intervention. R406, the first-in-man Syk inhibitor, was tested in a phase 1/2 study, in which 68 patients with recurrent Bcell lymphomas were enrolled. Among those were 11 CLL patients, who had the highest response rate (55%). Here, we tested the hypothesis that direct and specific Syk inhibition with the two Syk inhibitors PRT318 and P505-15 has the ability to inhibit CLL cell activation, migration and survival. PRT318 and P505-15 share a structural template and are both low nanomolar potency inhibitors of purified Syk. Our findings demonstrate that both, PRT318 and P505-15, are highly effective for inhibition of CLL cell responses to stimulation via the BCR, resulting in reduced CLL cell viability, chemokine secretion and signaling responses. The fact that PRT318 and P505-15 not only abrogated increased CLL cell viability after anti-IgM stimulation, but furthermore decreased CLL cell viability to levels lower than in untreated controls (Figures 1  and 2 ) is consistent with the previous notion of constitutively active Syk in CLL, 16, 36, 38, 39 which supports the maintenance of basal cell viability in CLL 38, 39 and other B-cell malignancies. The effects of PRT318 and P505-15 on CLL cell viability after anti-IgM and in NLC co-cultures are not substantially different from our experience with R406, 16 indicating that these are on-target, Syk-specific effects and suggesting that off-target effects of the relatively nonspecific inhibitor R406 do not have a major impact to CLL cell viability in our models. The data by Baudot et al., 39 using pharmacological inhibition of constitutive Syk activity and silencing by small interfering RNA, which caused a dramatic decrease in CLL viability, further support this concept.
One of the most remarkable effects of R406 and other inhibitors of BCR-associated kinases is their ability to cause rapid shrinkage of lymph nodes, which is typically accompanied by a substantial, transient lymphocytosis. 18, 27, 32 These clinical findings indicate that these kinase inhibitors cause a 'mobilization' or 'compartment shift' of CLL cells from the tissues into the peripheral blood, where CLL cells then are deprived from tissue-derived survival factors, which, along with Syk inhibition, causes CLL cell death and over time leads to remissions. Inhibition of chemokine receptor function in CLL cells by Syk inhibition 16, 17, 29 appears to be the central mechanism underlying this finding. Our finding that PRT318 and P505-15 effectively inhibit chemotaxis of CLL cells toward CXCL12 and CXCL13 (Figure 4 ) confirm earlier findings with R406 (refs 16,17) and again indicate that these effects are Syk specific. The importance of Syk for B-cell migration is further substantiated by recent findings demonstrating that SWAP-70, an F-actin-binding, Rho GTPase-interacting protein is activated by Syk. 29 SWAP-70 is expressed in activated B cells, and necessary for normal B-cell migration in vitro and in vivo. 40 The effects of PRT318 and P505-15 on chemokine secretion (CCL3, CCL4) by CLL cells after stimulation with anti-IgM and NLC points toward another important regulatory axis in the CLL microenvironment. Normally, these chemokines are selectively expressed and secreted by normal follicular B cells in response to BCR activation in order to attract T helper cells for cognate B --Tcell interactions. 41 In CLL, a similar mechanism appears to operate, 25 which presumably allows for T-cell attraction to BCRactivated CLL cells in proliferation centers, where CLL cells are in intimate contact with T cells. 6, 7 The inhibitory effects of PRT318 and P505-15 on CCL3 and CCL4 secretion is consistent with CCL3 and CCL4 being key BCR response genes. 13, 25 CCL3 and CCL4 also are emerging as useful markers for disease monitoring, given that CCL3 and CCL4 levels can easily be measured, 25 are prognostic 28 and can be useful for response assessment in CLL, 42 particularly in patients undergoing therapy with agents that target BCR signaling, as demonstrated for the phosphatidylinositol 3 kinase delta inhibitor CAL-101. 27 In summary, our study defines the activity of PRT318 and P505-15, two novel, highly specific Syk inhibitors, on CLL cell activation, survival and migration. The robust inhibitory actions of these inhibitors in our model systems provide the basis for the clinical development of these agents in CLL and other B-cell malignancies, and a roadmap for design of correlative studies on future clinical trials with Syk inhibitors.
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